Fibrotic focus in invasive ductal carcinoma: An indicator of high tumor aggressiveness

被引:57
作者
Hasebe, T
Tsuda, H
Hirohashi, S
Shimosato, Y
Iwai, M
Imoto, S
Mukai, K
机构
[1] NATL CANC CTR,RES INST,DIV PATHOL,KASHIWA,CHIBA 277,JAPAN
[2] NATL CANC CTR,DEPT SURG,KASHIWA,CHIBA 277,JAPAN
[3] NATL CANC CTR,RES INST,DIV PATHOL,TOKYO 104,JAPAN
[4] NATL CANC CTR,CLIN LAB DIV,CHUO KU,TOKYO 104,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1996年 / 87卷 / 04期
关键词
invasive ductal carcinoma; fibrotic focus; c-erbB-2; protein; p53; proliferating cell nuclear antigen;
D O I
10.1111/j.1349-7006.1996.tb00234.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histological examination of invasive ductal carcinoma of the breast often demonstrates the presence of an extensive central fibrotic focus (FF). The clinicopathological significance of the FF, or scar, in primary invasive ductal carcinoma is still ambiguous. One hundred and fifty-three cases of invasive ductal carcinoma (IDC) were classified into two groups, those with and those without FF. The differences in frequency of immunohistochemically detected overexpression of c-erbB-2 protein and nuclear accumulation of p53 protein, and the labeling index of proliferating cell nuclear antigen (PCNA), as well as histopathological parameters were compared between these two groups. IDCs smaller than 50 mm with FF showed a higher frequency of high-grade tumors, a higher frequency of lymph node metastasis, and a significantly higher frequency of c-erbB-2 protein overexpression than those without FF. In tumors of 20 mm or less, the incidence of nuclear accumulation of p53 protein was significantly higher in tumors with than those without FF. Tumors with FF showed a significantly higher PCNA labeling index than those without FF, regardless of tumor size. The present results indicate that the presence of FF is an important clinicopathological parameter associated with a higher degree of malignancy in IDCs, especially those smaller than 50 mm. Therefore, dividing IDCs into those with and those without FF appears to be meaningful clinicopathologically.
引用
收藏
页码:385 / 394
页数:10
相关论文
共 27 条
[1]   PROLIFERATING-CELL NUCLEAR ANTIGEN (PC10) IMMUNOLABELING AND OTHER PROLIFERATION INDEXES AS PROGNOSTIC FACTORS IN BREAST-CANCER [J].
AALTOMAA, S ;
LIPPONEN, P ;
PAPINAHO, S ;
SYRJANEN, K .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1993, 119 (05) :288-294
[2]  
[Anonymous], 1987, DIAGNOSTIC HISTOPATH
[3]  
[Anonymous], INSTR DET SUSC RES A
[4]   IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN MAMMARY-CARCINOMA - AN IMPORTANT NEW INDEPENDENT INDICATOR OF PROGNOSIS [J].
BARNES, DM ;
DUBLIN, EA ;
FISHER, CJ ;
LEVISON, DA ;
MILLIS, RR .
HUMAN PATHOLOGY, 1993, 24 (05) :469-476
[5]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[6]  
CLARK GM, 1991, CANCER RES, V51, P944
[7]  
ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300
[8]   ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE [J].
FINLAY, CA ;
HINDS, PW ;
TAN, TH ;
ELIYAHU, D ;
OREN, M ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :531-539
[9]   SCAR CANCERS - PATHOLOGIC FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST PROJECT (PROTOCOL NO. 4) .9. [J].
FISHER, ER ;
PALEKAR, AS ;
SASS, R ;
FISHER, B .
BREAST CANCER RESEARCH AND TREATMENT, 1983, 3 (01) :39-59
[10]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53